These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 23235192)
1. Questions and answers: what can be said by diagnostic imaging in neuroendocrine tumors? Cuccurullo V; Faggiano A; Scialpi M; Cascini GL; Piunno A; Catalano O; Colao A; Mansi L Minerva Endocrinol; 2012 Dec; 37(4):367-77. PubMed ID: 23235192 [TBL] [Abstract][Full Text] [Related]
2. Octreoscan Versus FDG-PET for Neuroendocrine Tumor Staging: A Biological Approach. Squires MH; Volkan Adsay N; Schuster DM; Russell MC; Cardona K; Delman KA; Winer JH; Altinel D; Sarmiento JM; El-Rayes B; Hawk N; Staley CA; Maithel SK; Kooby DA Ann Surg Oncol; 2015 Jul; 22(7):2295-301. PubMed ID: 25786743 [TBL] [Abstract][Full Text] [Related]
3. Radiological and nuclear medicine imaging of gastroenteropancreatic neuroendocrine tumours. Sundin A Best Pract Res Clin Gastroenterol; 2012 Dec; 26(6):803-18. PubMed ID: 23582920 [TBL] [Abstract][Full Text] [Related]
4. Diagnostic imaging approach to gastro-entero-pancreatic carcinomas of neuroendocrine origin - single NET center experience in Poland. Cwikla JB; Nasierowska-Guttmejer A; Jeziorski KG; Cichocki A; Zgliczynski W; Stepień K; Seklecka N; Durlik M; Malkowski B; Walecki J Neuro Endocrinol Lett; 2007 Dec; 28(6):789-800. PubMed ID: 18063942 [TBL] [Abstract][Full Text] [Related]
5. Imaging of neuroendocrine gastro-entero-pancreatic tumours using radiolabelled somatostatin analogues. Chiti A; van Graafeiland BJ; Savelli G; Ferrari L; Seregni E; Castellani MR; Bombardieri E Ital J Gastroenterol Hepatol; 1999 Oct; 31 Suppl 2():S190-4. PubMed ID: 10604128 [TBL] [Abstract][Full Text] [Related]
6. [Diagnosis, staging and follow-up of neuroendocrine tumors: role of somatostatin receptors scintigraphy]. Lebtahi R Ann Pathol; 2011 Nov; 31(5 Suppl):S83-4. PubMed ID: 22054471 [No Abstract] [Full Text] [Related]
7. [Imaging and radioguided surgery of tumors NETs]. Schillirò F; Mallardo V; Manna A; Fontanarosa A; Califano T; Della Vecchia N; Romano G; Di Crescenzo V; Genovese EA Recenti Prog Med; 2013; 104(7-8):336-9. PubMed ID: 24042403 [TBL] [Abstract][Full Text] [Related]
8. Nuclear Medicine in Patients with NET: Radiolabeled Somatostatin Analogues and their Brothers. Cuccurullo V; Prisco MR; Di Stasio GD; Mansi L Curr Radiopharm; 2017; 10(2):74-84. PubMed ID: 28332450 [TBL] [Abstract][Full Text] [Related]
10. Role of 18F-dopa PET/CT imaging in the management of patients with 111In-pentetreotide negative GEP tumours. Ambrosini V; Tomassetti P; Rubello D; Campana D; Nanni C; Castellucci P; Farsad M; Montini G; Al-Nahhas A; Franchi R; Fanti S Nucl Med Commun; 2007 Jun; 28(6):473-7. PubMed ID: 17460538 [TBL] [Abstract][Full Text] [Related]
11. Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in diagnosis and management of pancreatic cancer; comparison with multidetector row computed tomography, magnetic resonance imaging and endoscopic ultrasonography. Ergul N; Gundogan C; Tozlu M; Toprak H; Kadıoglu H; Aydin M; Cermik TF Rev Esp Med Nucl Imagen Mol; 2014; 33(3):159-64. PubMed ID: 24140024 [TBL] [Abstract][Full Text] [Related]
12. [Diagnostics and treatment of neuroendocrine tumors of the digestive tract in the light of the present standards]. Szczeblowska D Pol Merkur Lekarski; 2007 May; 22(131):437-41. PubMed ID: 17679390 [TBL] [Abstract][Full Text] [Related]
13. [Radionuclide imaging of neurendocrine tumors: biological basis and diagnostic results]. Genovese EA; Mallardo V; Rossi M; Vaccaro A; Raucci A; Della Vecchi N; Romano G; Califano T; Schillirò F Recenti Prog Med; 2013; 104(7-8):340-4. PubMed ID: 24042404 [TBL] [Abstract][Full Text] [Related]